# H3N2 M2SR in Pediatric Population

> **NCT03553940** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 43 (actual)

## Conditions studied

- Influenza
- Influenza Immunisation

## Interventions

- **BIOLOGICAL:** Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine
- **OTHER:** Placebo
- **BIOLOGICAL:** Quadrivalent MDCK Inactivated Influenza Vaccine

## Key facts

- **NCT ID:** NCT03553940
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-15
- **Primary completion:** 2020-08-27
- **Final completion:** 2020-08-27
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2021-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03553940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03553940, "H3N2 M2SR in Pediatric Population". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03553940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*